S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market

CureVac (CVAC) Competitors

$2.44
0.00 (0.00%)
(As of 04/19/2024 ET)

CVAC vs. COGT, ZYME, LBPH, SIGA, PHAR, SVRA, MLYS, CALT, OLMA, and LYEL

Should you be buying CureVac stock or one of its competitors? The main competitors of CureVac include Cogent Biosciences (COGT), Zymeworks (ZYME), Longboard Pharmaceuticals (LBPH), SIGA Technologies (SIGA), Pharming Group (PHAR), Savara (SVRA), Mineralys Therapeutics (MLYS), Calliditas Therapeutics AB (publ) (CALT), Olema Pharmaceuticals (OLMA), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical preparations" industry.

CureVac vs.

CureVac (NASDAQ:CVAC) and Cogent Biosciences (NASDAQ:COGT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

CureVac presently has a consensus price target of $15.00, suggesting a potential upside of 514.75%. Cogent Biosciences has a consensus price target of $13.67, suggesting a potential upside of 103.68%. Given CureVac's higher probable upside, equities analysts plainly believe CureVac is more favorable than Cogent Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CureVac
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cogent Biosciences
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71

Cogent Biosciences has lower revenue, but higher earnings than CureVac.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVac$72.33M7.55-$262.38MN/AN/A
Cogent BiosciencesN/AN/A-$192.41M-$2.40-2.80

Cogent Biosciences received 250 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 70.65% of users gave Cogent Biosciences an outperform vote while only 53.66% of users gave CureVac an outperform vote.

CompanyUnderperformOutperform
CureVacOutperform Votes
22
53.66%
Underperform Votes
19
46.34%
Cogent BiosciencesOutperform Votes
272
70.65%
Underperform Votes
113
29.35%

In the previous week, CureVac had 6 more articles in the media than Cogent Biosciences. MarketBeat recorded 7 mentions for CureVac and 1 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.34 beat CureVac's score of -0.56 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CureVac
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Negative
Cogent Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

17.3% of CureVac shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 5.1% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CureVac's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
CureVacN/A N/A N/A
Cogent Biosciences N/A -86.67%-58.11%

CureVac has a beta of 2.51, suggesting that its stock price is 151% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.

Summary

CureVac and Cogent Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CVAC vs. The Competition

MetricCureVacPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$546.27M$6.42B$4.88B$7.32B
Dividend YieldN/A3.10%2.92%3.97%
P/E RatioN/A9.04179.4516.66
Price / Sales7.55307.642,464.8581.89
Price / CashN/A28.9747.3834.38
Price / Book0.855.324.564.15
Net Income-$262.38M$140.57M$104.42M$214.00M
7 Day Performance-16.15%-6.71%-4.52%-3.51%
1 Month Performance-19.74%-9.68%-6.81%-6.05%
1 Year Performance-69.50%-6.66%6.58%3.98%

CureVac Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COGT
Cogent Biosciences
1.5028 of 5 stars
$6.99
+7.2%
$13.67
+95.5%
-39.7%$668.31MN/A-2.91164
ZYME
Zymeworks
0.8777 of 5 stars
$9.36
-2.7%
$15.00
+60.3%
-10.0%$660.54M$76.01M-5.38272News Coverage
LBPH
Longboard Pharmaceuticals
1.4824 of 5 stars
$18.58
+2.2%
$39.50
+112.6%
+137.0%$669.25MN/A-7.8150Analyst Report
SIGA
SIGA Technologies
0.6596 of 5 stars
$9.27
+3.0%
N/A+41.4%$659.00M$139.92M9.7645Options Volume
PHAR
Pharming Group
2.4802 of 5 stars
$10.00
-6.1%
$37.00
+270.0%
-8.6%$671.11M$245.32M-71.42332News Coverage
Positive News
Gap Down
High Trading Volume
SVRA
Savara
1.6369 of 5 stars
$4.90
+4.7%
$8.20
+67.3%
+161.4%$676.94MN/A-14.85N/AAnalyst Report
News Coverage
Positive News
MLYS
Mineralys Therapeutics
1.9483 of 5 stars
$13.14
-0.9%
$33.50
+154.9%
-18.0%$652.14MN/A-6.5728Positive News
CALT
Calliditas Therapeutics AB (publ)
2.8402 of 5 stars
$21.73
+1.0%
$34.00
+56.5%
-21.4%$647.34M$113.78M-13.25192News Coverage
OLMA
Olema Pharmaceuticals
1.8304 of 5 stars
$11.53
+2.3%
$21.43
+85.9%
+141.0%$644.76MN/A-5.3474News Coverage
LYEL
Lyell Immunopharma
1.3983 of 5 stars
$2.52
+15.1%
$5.50
+118.3%
-0.4%$640.33M$130,000.00-2.71224News Coverage

Related Companies and Tools

This page (NASDAQ:CVAC) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners